Trial Profile

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 19 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy Leman Biotech (Primary)
Indications Diffuse large B cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

19 Nov 2023 Inclusion criteria is updated to change the age limits from >/= 18 years to 3 to 70 years, thus including elderly, child and adolescents also.
07 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com